Anti-ADIPOQ antibody (C-Term) [M576] (STJA0005247)

SKU:
STJA0005247-100

Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Adiponectin (C-Term) is suitable for use in Western Blot research applications.
Clonality: Monoclonal
Clone ID: M576
Conjugation: Unconjugated
Isotype: IgG1
Formulation: PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol
Purification: Protein G Purified
Dilution Range: WB 1:500
IHC
ICC
IP
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: Adipoq
Gene ID: 11450
Uniprot ID: ADIPO_MOUSE
Immunogen Region: C-Term
Specificity: This antibody detects a 30 kDa* protein on SDS-PAGE immunoblots of human and mouse serum, as well as detects full length human and mouse recombinant proteins.
Immunogen: Clone (M576) was generated from a recombinant protein that included amino acid residues within the C-terminal region of mouse Adiponectin. This sequence has high homology with similar regions in rat and human adiponectin.
Tissue Specificity Synthesized exclusively by adipocytes and secreted into plasma.
Post Translational Modifications HMW complexes are more extensively glycosylated than smaller oligomers. Hydroxylation and glycosylation of the lysine residues within the collagen-like domain of adiponectin seem to be critically involved in regulating the formation and/or secretion of HMW complexes and consequently contribute to the insulin-sensitizing activity of adiponectin in hepatocytes. O-glycosylated. Not N-glycosylated O-linked glycans on hydroxylysine residues consist of Glc-Gal disaccharides bound to the oxygen atom of post-translationally added hydroxyl groups. O-linked glycosylation in the N-terminal is disialylated with the structure Neu5Acalpha2->8Neu5Acalpha2->3Gal. Sialylated by alpha 2,8-sialyltransferase III. Succination of Cys-39 by the Krebs cycle intermediate fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits polymerization and secretion of adiponectin. Adiponectin is a major target for succination in both adipocytes and adipose tissue of diabetic mice. It was proposed that succination of proteins is a biomarker of mitochondrial stress and accumulation of Krebs cycle intermediates in adipose tissue in diabetes and that succination of adiponectin may contribute to the decrease in plasma adiponectin in diabetes.
Function Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW.
Protein Name Adiponectin
30 Kda Adipocyte Complement-Related Protein
Adipocyte Complement-Related 30 Kda Protein
Acrp30
Adipocyte - C1q And Collagen Domain-Containing Protein
Adipocyte-Specific Protein Adipoq
Database Links Reactome: R-MMU-163680
Cellular Localisation Secreted
Alternative Antibody Names Anti-Adiponectin antibody
Anti-30 Kda Adipocyte Complement-Related Protein antibody
Anti-Adipocyte Complement-Related 30 Kda Protein antibody
Anti-Acrp30 antibody
Anti-Adipocyte - C1q And Collagen Domain-Containing Protein antibody
Anti-Adipocyte-Specific Protein Adipoq antibody
Anti-Adipoq antibody
Anti-Acdc antibody
Anti-Acrp30 antibody
Anti-Apm1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance